Candel Therapeutics, Inc.
30-Day Trend
CADL (Candel Therapeutics, Inc.) is ranked #86 on the All Score, up from #283 (+197) across StockTwits, Korea, China, Germany, and Japan retail investor sources.
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Yahoo · Oct 29, 2026
Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting
Benzinga · Oct 29, 2026
Candel Therapeutics to Present at November Investor Conferences
Yahoo · Oct 27, 2026
US market headlines from third-party sources. Updated daily.
Updated
